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Summary
 
CD59 is a widely distributed membrane-bound inhibitor of the cytolytic membrane attack
complex (MAC) of complement. This small (77 amino acid) glycoprotein is a member of the
Ly6 superfamily of proteins and is important in protecting host cells from the lytic and proin-
flammatory activity of the MAC. CD59 functions by binding to C8 and/or C9 in the nascent
MAC and interfering with C9 membrane insertion and polymerization. We present data ob-
tained from a combination of molecular modeling and mutagenesis techniques, which together
indicate that the active site of CD59 is located in the vicinity of a hydrophobic groove on the
face of the molecule opposite to a “hydrophobic strip” suggested earlier. In addition, removal
of the single N-linked glycosylation site at Asn18 of CD59 resulted in an enhancement of
complement inhibitory activity.
 
A
 
ctivation of complement results in the formation of
the proteolytic C3/C5 convertases, which can initiate
formation of the cytolytic membrane attack complex
(MAC)
 
1
 
. The MAC is formed by the sequential assembly
of the terminal complement proteins C5b, C6, C7, C8, and
multiple C9s. Under normal circumstances, complement is
activated by, and directed against invading microorganisms.
However, under certain circumstances, most notably in
some autoimmune and inflammatory conditions, comple-
ment can also become deposited on host cells. In addition
to causing cell lysis, sublethal concentrations of MAC as-
sembled on host cells mediate various inflammatory pro-
cesses that can elicit severe pathophysiological effects. Host
cell membranes are protected from homologous MAC by
CD59, a small glycoprotein attached to the plasma mem-
brane by a glycosylphosphatidylinositol (GPI) anchor. The
mature protein consists of 77 amino acids arranged in a
single cysteine-rich domain composed of two antiparallel
 
b
 
-sheets, 5 protruding surface loops and a short helix (1, 2).
CD59 functions by binding to C8
 
a
 
 and/or C9 in the as-
sembling MAC and interfering with C9 membrane inser-
tion and polymerization (3–6).
Several studies have demonstrated the potential useful-
ness of recombinant soluble complement regulatory pro-
teins for therapy of autoimmune and inflammatory disease
(7–11). In addition, MAC-mediated tissue destruction is
primarily responsible for hyperacute rejection of porcine
organs transplanted into primates, a result of complement
activation by natural antibodies (12). CD59 and other
complement inhibitors display varying degrees of species
selectivity. The expression of human CD59 on transgenic
animal organs protects them from human complement-medi-
ated damage and prolongs their survival after transplantation
into baboons (13–16). There is thus much interest in the
potential use of CD59 and other complement inhibitors,
either soluble or expressed on the surface of transgenic pig
organs, in human transplantation.
CD59 belongs to the Ly6 superfamily of proteins which
includes functional CD59 analogues from other species,
snake venom neurotoxins, urokinase-type plasminogen ac-
tivator receptor and murine Ly6 differentiation antigens (17).
Mouse Ly6E antigen (18) is a structural but not functional
analogue of CD59 (see Fig. 1). In the approach reported
here, functionally important regions of CD59 were deter-
mined by replacing regions of Ly6E with corresponding re-
gions from CD59 and assaying expressed chimeric proteins
for activity. The active site was then further defined by a
series of site-specific mutations, selected as a result of com-
paring evolutionary conserved residues and modeling of
the molecular surface of CD59.
 
Materials and Methods
 
Cells and DNA.
 
All DNA manipulations were carried out in
the mammalian expression vector pCDNA3 (Invitrogen, San Di-
ego, CA) containing either CD59 or Ly6E cDNA subcloned into
its multiple cloning site. pCDNA3 contains a G418 resistance
marker. CD59 and Ly6E cDNA were kind gifts from Drs. H.
Okada (Nagoya City University, Nagoya, Japan) and U. Häm-
merling (Memorial SloanKettering Cancer Center, New York),
respectively. Chinese hamster ovary cells (CHO) were used for
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protein expression and were maintained in Dulbecco’s modified
essential medium (DMEM) supplemented with 10% FCS. Stably
transfected CHO cell lines were selected after the cultivation of
cells in the presence of G418 (GIBCO BRL, Gaithersburg, MD).
 
Antibodies and Serum.
 
Rabbit antisera to CHO cell mem-
branes, CD59 and to CD59-specific peptide were prepared by
standard techniques (19). CHO cell membranes were prepared as
described (20). CD59 antigen was prepared from human eryth-
rocytes as described (21). The peptide antigen corresponded to
the COOH-terminal sequence of mature CD59 (CKKDLCN-
FNEQLE) and was conjugated to KLH for immunization. Pep-
tide synthesis and KLH conjugation was performed by Genemed
(South San Francisco, CA). Anti-CD59 peptide Ab was affinity
purified by means of peptide immobilized onto CNBr-activated
sepharose (Pharmacia, Piscataway, NJ). Anti-CD59 mAbs YTH53.1,
MEM43/5, and HC1 were kindly provided by Dr. B.P. Morgan
(University of Wales, Cardiff, UK). Each recognize nonoverlap-
ping conformational epitopes on CD59 (22). mAb 2A10 (23) is di-
rected against (NANP)
 
n
 
, a repeat domain of 
 
Plasmodium falciparum
 
circumsporozoite protein. FITC-conjugated Abs used for flow
cytometry were purchased from Sigma Chem. Co. (St. Louis,
MO). Normal human serum (NHS) was obtained from the blood
of healthy volunteers in the laboratory and stored at 
 
2
 
70
 
8
 
C.
 
Mutant Construction.
 
Based on the alignment of CD59 and
Ly6E amino acid sequences (Fig. 1), cDNA encoding the chi-
meric constructs depicted in Fig. 2 were prepared. Segments of
either CD59 or Ly6E cDNA were generated and joined using
PCR. The general procedure used for the generation of chimeric
constructs was as described (24). The 5
 
9
 
 and 3
 
9
 
 end primers,
which matched an untranslated sequence of either CD59 or Ly6E,
included a HindIII and ApaI site, respectively. Using either CD59
or Ly6E cloned into pCDNA3 as template, these primers were
paired in a PCR with CD59-Ly6E chimeric primers that spanned
the desired crossover point. The PCR products were purified
from agarose gel after electrophoresis and used in a second ampli-
fication with the primers corresponding to 5
 
9
 
 or 3
 
9
 
 untranslated
regions. The resulting full-length CD59-Ly6E chimeric cDNAs
were cloned into the HindIII/ApaI sites of pCDNA3 for se-
quencing and expression. Five site-specific point mutations in
CD59 (N18Q, F23D, Y36F, W40Y, and L54N) were prepared
by PCR using similar techniques. In the first PCR amplification,
5
 
9
 
 and 3
 
9
 
 primers to CD59 untranslated region were paired with
Figure 1. CD59 and Ly6E se-
quence comparison. Mature pro-
tein sequences are shown with
the conserved cysteine residues
marked (:). The amino acids
forming the surface loops and
helix of CD59 are shown. The
COOH-terminal end of mature
Ly6E is predicted.
Figure 2. Diagram of CD59-
Ly6E chimeric constructs. All
numbers refer to amino acid po-
sitions of CD59. 
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primers spanning the target site, and which contained a substi-
tuted codon at the target site. An epitope tag was engineered into
CD59-Ly6E chimeric proteins between the first and second
amino acids of mature CD59. The NH
 
2
 
-terminal Leu was dupli-
cated at the COOH-terminus of the tag. A 36mer oligonucleotide
encoding NANPNANPNA and with appropriate overhangs was
inserted at the PstI restriction site of each point-specific mutant,
and of CD59 and CD-Ly constructs (chimeras with CD59 at the
NH
 
2
 
 terminus).
 
CHO Cell Transfection and Selection.
 
pCDNA3 constructs were
transfected into CHO cells that were 50–75% confluent. Trans-
fections were carried out with lipofectamine according to the
manufacturer’s instructions (GIBCO BRL). 3 d after transfection,
recombinant protein expression was confirmed, and G418 was
added to the medium for selection of stably transfected popula-
tions. After 2 wk in selection medium, cells were fluorescently la-
beled by means of appropriate Abs and sorted by flow cytometry.
Stable populations of CHO cells each expressing similar relative
levels of recombinant proteins on their surface were isolated by
repeated rounds of cell sorting using either the tag-specific mAb
2A10 (for CD59, CD-Ly chimeras, and point mutants) or anti-
peptide Ab (for Ly-CD proteins). Three rounds of sorting were
usually sufficient to obtain uniform cell populations that were stable
for several weeks. Stably transfected CHO cell clones expressing
CD59, unglycosylated CD59 and NH
 
2
 
 terminus tagged CD59
were prepared according to instructions supplied by GIBCO BRL
with lipofectamine reagent.
 
Flow Cytometry.
 
Analysis of cell surface protein expression
was performed by flow cytometry using a Beckton Dickinson
FACScan
 
Ò
 
. Detached CHO cells were incubated with appropri-
ate Ab for 30 min at 4
 
8
 
C, washed by centrifugation, incubated
with appropriate FITC-conjugated second Ab (30 min/4
 
8
 
C), and
washed again before fixation with 2% paraformaldehyde in PBS.
All incubations and washing were performed in DMEM/10% FCS.
The following Abs and concentrations were used: rabbit anti-
COOH-terminal CD59 peptide Ab (30 
 
m
 
g/ml); rabbit anti-CD59
antiserum (1:100); anti-CD59 mAb YTH53.1 IgG (10 
 
m
 
g/ml); anti-
tag mAb 2A10 and anti-CD59 mAb MEM 43/5 ascites (1:250);
anti-CD59 mAb HC1 culture supernatant (1:25). FITC-conju-
gated secondary Abs were used between 1:100 and 1:400 final
concentration. Cells for sorting were fluorescently labeled follow-
ing the procedure above but without fixation. Sorting was done
in a Coulter Epics Elite with EPS sort module.
 
Cell Lysis Assays.
 
Subconfluent CHO cells were detached
with versene (GIBCO BRL), washed once and resuspended to 1 
 
3
 
10
 
6
 
/ml in DMEM/10% FCS. An equal volume of calcein-AM
(5 
 
m
 
g/ml) (Molecular Probes, Eugene, OR) in DMEM was
added and the cells incubated for 15 min at 37
 
8
 
C. The cells were
then washed twice, resuspended to their original concentration in
DMEM/10% FCS and incubated with rabbit anti-CHO cell mem-
brane antiserum (20% final concentration) for 30 min on ice. The
sensitized cells were then centrifuged, resuspended to their original
concentration and an equal volume of NHS diluted in DMEM
added. After 1 h at 37
 
8
 
C, the cells were centrifuged and cell lysis
assessed by measuring released fluorescence in the supernatant.
Measurements were performed in microtiter plates using a Lab-
systems fluoroscan II set to read at excitation 485 nm and emis-
sion 538 nm. Cells were lysed with 0.01% saponin for 100% lysis
controls. Cell lysis assays were typically performed in 1.5-ml mi-
crofuge tubes in a final volume of 200 
 
m
 
l (1 
 
3
 
 10
 
5
 
 cells). Cell lysis
assays were also performed using propidium iodide, which fluo-
rescently stains dead cells. CHO cells were sensitized to comple-
ment as described and 100 
 
m
 
l cells (1 
 
3
 
 10
 
6
 
/ml) mixed with
NHS dilutions. After 60 min at 37
 
8
 
C, propidium iodide was added
(10 
 
m
 
g/ml final) and cell lysis determined by flow cytometry.
 
Molecular Modeling.
 
A CD59 analytical molecular surface,
which is defined as the smooth envelope touching the van der
Waals surface of atoms as the solvent probe rolls over the protein
molecule, was built with the contour-buildup algorithm (25) as
implemented in the ICM program (26). A probe sphere of 1.4 A
was used. Molecular models of the point mutants were built and
analyzed using the following procedures: (
 
a
 
) the structure of
CD59 (pdb-code 1cds) solved by NMR (1) was carefully energy
minimized; (
 
b
 
) appropriate residue modifications introduced; (
 
c
 
)
the mutated side-chains were energy minimized using the biased
probability Monte Carlo sample of the side-chain torsions (27),
(
 
d
 
) interactions were analyzed by visual inspection using the ICM
program.
 
Results
 
Role of N-linked Carbohydrate in CD59 Function. 
 
Native
CD59 is glycosylated at Asn18, and there are conflicting
reports concerning its functional importance (28–30). We
substituted Asn18 with Gln, and expressed the mutant pro-
tein in CHO cells. Fig. 3 shows that CHO cells expressing
recombinant wild-type and unglycosylated CD59 are much
more resistant to lysis by complement than mock trans-
fected controls. Two stable CHO cell clones expressing
unglycosylated CD59 were isolated, and each was matched
with a CHO cell clone expressing a similar level of native
CD59 for functional assays (Table 1). In both cases, cells
expressing unglycosylated CD59 were more resistant to com-
plement than cells expressing similar levels of native CD59.
The difference was small but significant (
 
P
 
 
 
,
 
0.05) over a
range of serum concentrations. The expected reduction in
MW of unglycosylated CD59 was confirmed by Western
blotting of CHO cell membrane preparations (not shown).
 
Complement Inhibitory Activity of CD59/Ly6E Chimeric
Proteins.
 
To identify regions of CD59 important for func-
tion, a series of CD59/Ly6E chimeric proteins containing
Figure 3. Complement inhibitory activity of unglycosylated CD59.
Stable CHO cell clones expressing similar levels of CD59 or unglycosy-
lated CD59 (N18Q) were assayed for their susceptibility to complement.
Controls were mock transfected CHO cells. Each point represents the
mean of at least four determinations. 
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either CD59 or Ly6E at their NH
 
2
 
-terminus were ex-
pressed on CHO cells. We reasoned that the residues in-
volved in ligand binding were probably located in surface
loops. For this reason, most of the chosen switch over
points between CD59 and Ly6E were at selected loop
boundaries (see Fig. 2).
CHO cell populations expressing similar levels of re-
combinant CD59 or chimeric proteins were assayed for
their susceptibility to human complement. The functional
data obtained with the CD-Ly chimeras (CD59 at NH
 
2
 
 ter-
minus) revealed that the region of CD59 which lies COOH-
terminal to residue 57 is not required for function; both
CD-Ly 57 and CD-Ly 64 possessed the same specific activ-
ity as wild type CD59 (Fig. 4). The other CD-Ly chimeras
which contained shorter CD59-specific sequences had no
complement inhibitory activity. Of the Ly-CD chimeras
(Ly6E at NH
 
2
 
 terminus), only Ly-CD 16 possessed any
functional activity (Fig. 4). The specific activity of Ly-CD
16 was 
 
z
 
85% that of wild-type CD59. Taken together,
these data indicate that the functionally important region of
CD59 is located between amino acids 16 and 57 in the pri-
mary structure.
To quantitate the relative surface expression of CD59
and CD-Ly chimeric proteins, a 10–amino acid epitope tag
was engineered onto the NH
 
2
 
 termini of the constructs.
The tag did not affect the expression (Table 1) or the func-
tion (Fig. 5) of CD59. However, when the tag was placed
at the NH
 
2
 
 terminus of Ly6E in the Ly-CD constructs, it
interfered with expression and function of the chimeras.
Therefore, surface expression of Ly-CD chimeras was
quantitated using a rabbit Ab against a peptide correspond-
ing to a sequence from the COOH terminus of CD59 (Ta-
ble 1). This Ab reacted quantitatively with CHO cell clones
stably expressing different levels of CD59 (not shown). Cell
populations used in these experiments were obtained by
several rounds of cell sorting, and separate CD-Ly and Ly-
 
Table 1.
 
Flow Cytometric Analysis of Stable CHO Cell Clones and Sorted CHO Cell Populations Expressing CD59 and Mutant Constructs
 
Transfectant
Mean Relative Fluorescence
Anti-CD59
polyclonal
Anti-tag
mAb 2A10
Anti-CD59 peptide
polyclonal
Anti-CD59
mAb YTH53.1
Anti-CD59
mAb MEM43/5
Anti-CD59
mAb HC1
CD59 1246
 
22
 
1218
 
22
 
CD59-tagged 1207 695
 
2
 
1119
 
22
 
CD59 (1) 1314
 
22
 
1299
 
22
 
N18Q (1) 1196
 
22
 
1201
 
22
 
CD59 (2)
 
2
 
289
 
22
 
N18Q (2)
 
2
 
221
 
22
 
CD59 (CD-Ly set)
 
2
 
820
 
22 2 2
 
CD-Ly 24
 
2
 
1220
 
22 2 2
 
CD-Ly 47
 
2
 
894
 
22 2 2
 
CD-Ly 57
 
2
 
798
 
22 2 2
 
CD-Ly 64
 
2
 
980
 
22 2 2
 
CD59 (Ly-CD set)
 
22
 
632
 
22 2
 
Ly-CD 16
 
22
 
561
 
22 2
 
Ly-CD 31
 
22
 
516
 
22 2
 
Ly-CD 39
 
22
 
616
 
22 2
 
CD59 (1)
 
2
 
986
 
2
 
766 460 826
CD59 (F23D)
 
2
 
780
 
2
 
727 448 770
CD59 (Y36F)
 
2
 
812
 
2
 
686 404 770
CD59 (2)
 
2
 
305
 
2
 
480 242 434
CD59 (L54N)
 
2
 
240
 
2 316 165 376
CD59 (W40Y) 23 22 12 22
Mean relative fluorescence of mock transfected CHO cells was below 20 with all Abs. Figures are relative within each grouped set.749 Yu et al.
CD sets were prepared, each with a corresponding CHO
cell population expressing a similar level of CD59.
Modeling the Molecular Surface of CD59. To reveal the
hypothetical location and extent of the functional site, we
built a model of the molecular surface of CD59 and ana-
lyzed: (a) the three-dimensional location of the fragments
that can be replaced by the Ly6E fragments, (b) the distri-
bution of surface patches that are conserved between CD59
of seven different species that are either closely related to
human, or that have been shown to inhibit human comple-
ment (Fig. 6), and finally, (c) the surface shape. A very clear
picture emerged from this analysis. Fig. 7 a displays the
molecule in an orientation that shows that the regions of
CD59 that can be replaced by Ly6E without loss of func-
tion (1-16 and 57-77) are located at the backside of the
molecule (in yellow, Fig. 7 a). From the position of residue
77, to which the GPI membrane anchor is attached, it can
be predicted that the active site is located on the exposed
face of the molecule.
Comparison of CD59 sequences within the region re-
quired for function (residues 16-57, Fig. 6) reveal a number
of evolutionary conserved residues (Fig. 6). However, of
these residues, only five are located on the surface of the
shown face of the molecule, and three (Y36, W40, and
L54) are conspicuously grouped together in a deep groove
(Fig. 7 b, conserved residues colored green). Furthermore,
conserved residue classes (Fig. 7 b, colored blue) are located
above and below the conserved residues within this groove.
From top to bottom these residue positions are (refer to
Fig. 7 b): no. 31: Ala or Ser, a small residue, presumably
important to keep the hypothetical binding groove open;
no. 59: Leu or Val, a hydrophobic residue, outside the
CD59 16-57 sequence, but conserved in Ly6E; no. 36:
Tyr, no. 54 Leu and no. 40 Trp, conserved residues; no.
23: Phe or Leu, a hydrophobic residue, and no. 41: Lys or
Arg, the only charged residues. The only addition to this
list of conserved residues at the shown face of the molecule
are Val 35 and two conserved Cys-Cys bridges (Cys19-
Cys39, and Cys6-Cys13, shown in yellow). Val 35 and
Cys6-Cys13 are located at the inner surface of a tunnel, an
interesting structural feature of the molecule (these residues
are obscured by the tunnel in Fig. 7 b). The conserved cys-
teines are most likely necessary for conservation of the to-
pology of the molecule.
Effect of Point Mutations within the Predicted Functional Site
of CD59. The three conserved residues (shown in green,
Fig. 7 b) and the conserved hydrophobic residue at position
F23 within the putatively identified binding groove of
CD59 were individually targeted for site-specific mutagen-
Figure 4. Complement resistance of CHO cells expressing CD59 and
CD59-Ly6E chimeric proteins. Complement resistance of CHO cell
populations expressing similar levels of either CD59-Ly6E or Ly6E-
CD59 chimeras was compared to cells expressing similar levels of CD59.
Cells were exposed to 10% NHS. Depending on whether the chimeric
protein contained CD59 at its NH2 or COOH terminus, different meth-
ods were used to quantitate relative expression. Therefore activity of chi-
meras should be compared to CD59 activity within each set.
Figure 5. Complement inhibitory activity of epitope tagged and un-
tagged CD59. Stable CHO cell clones expressing similar levels of CD59
or CD59 containing an NH2-terminal peptide tag (NANPNANPNA),
were assayed for their susceptibility to complement. Expression was quan-
titated using anti-CD59 mAb YTH53.1 and rabbit anti-CD59 Ab.
Figure 6. Amino acid sequence alignment of CD59 and CD59 homo-
logues from different species. The conserved residues located in the
groove that are shown in green in Fig. 7 b are in bold, and conserved res-
idue classes shown in blue in Fig. 7 b are underlined. Residues 16-57 are
shown in plain text. Note that not all of the conserved residues indicated
above occur on the shown surface of the molecule displayed in Fig. 7 b.
The sequences that can be replaced by Ly6E, and which are therefore not
required for function are in italics. Sequences shown are human CD59
(39) and homologues from Baboon (40), Marmoset (41) (GenBank acc.
no. L22860). African green monkey (40), Owl monkey (41) (GenBank
accession no. L22861), Rat (42), and Herpes Saimiri virus (43).750 Mapping the Active Site of DC59
esis. The four mutant CD59s prepared were F23D (Phe at
position 23 changed to Asp), Y36F, W40Y and L54N. The
amino acids used for the substitutions were chosen to have
similar shape but different physico-chemical properties.
The W40Y mutant was not stably expressed on the surface
of transfected CHO cells. Of the three expressed mutant
proteins, L54N had almost no function, F23D retained
some but significantly reduced function, and Y36F had
normal function (Fig. 8). For unknown reasons, only rela-
tively moderate levels of the L54N mutant protein could
be expressed on CHO cells, but activity was compared
with CHO cells expressing similar levels of wild-type
CD59 (see Table 1). In an attempt to assess whether the
mutant proteins were correctly folded, we studied their re-
activity with three different mAbs that each bind to non-
overlapping conformational epitopes on CD59. All mutant
proteins were recognized by these antibodies (Table 1).
Discussion
The results in this report represent a first approximation
at defining the active site of CD59. We have shown that:
(a) glycosylation of CD59 at Asn18 is not required for
function; (b) replacement of CD59 sequences 1-16 and 57-
77 with those of non-functional Ly6E did not affect CD59
activity. These regions are therefore not required for CD59
activity, and they map to the backside of the molecule that
is closer to the cell surface (Fig. 7 a); (c) a comparison of se-
quences of human CD59 and CD59 homologues from
other species within the identified functional region (amino
acids 16-57), reveal an almost linear arrangement of con-
served residues and residue classes in the three dimensional
structure. These residues were predominantly hydrophobic
in character, and were not contiguous in the primary struc-
ture. Together they marked a groove across the molecule
(Fig. 7 b); (d) mutation of residues within this groove dis-
rupted the function of the expressed mutant proteins.
Taken together, these data indicate that the active site of
CD59 is on the front (facing away from membrane) face of
the molecule and involves residues located along a hydro-
phobic groove defined by evolutionary conserved residues.
In further support of this conclusion, it was recently shown
that a correctly folded W40E mutant (residue located within
hydrophobic groove, Fig. 7 b) expressed on the surface of
CHO cells was inactive (Rushmere, N.K., D.L. Bodian,
S.J. Davis, S. Tomlinson, and B.P. Morgan. 1996. XVIth
International Complement Workshop. Boston, MA). In a
previous report, Kieffer et al. (2) suggested that a relatively
hydrophobic strip composed of exposed Tyr and Phe resi-
dues may constitute the functional site of CD59. Of note
however, these residues are located on the opposite face
and perpendicular to the hydrophobic groove identified in
this report.
All but one of the Ly-CD and CD-Ly chimeric proteins
expressed on CHO cells possessed either full or zero activ-
ity, making interpretation of data simple. The Ly-CD 16
chimera displayed slightly less (z15%) activity than wild
type CD59. The simplest explanation for this, taking into
account the modeling and point mutation data, is that the
NH2-terminal sequence of Ly6E causes a change in the ter-
tiary conformation of the active site of CD59. We cannot
Figure 7. Diagram of CD59. (a) Ribbon diagram (1). Conserved resi-
dues (Tyr36, Trp40, and Leu54) and Phe23 (always hydrophobic) which
were mutated for functional studies are shown. The two fragments of the
protein (1-16 and 57-77) that can be replaced with Ly6E sequence with-
out affecting function are shown by yellow ribbon. (b) Molecular surface
of CD59. The exposed surface patches of all of the evolutionary con-
served residues that occur between positions 16-57 on the displayed face
of the molecules are shown (green patches). Conserved residue classes are
shown in blue (refer to text for details). The colored patches represent the
molecular surface of the side chains of conserved residues and residue
classes.751 Yu et al.
exclude however, that the NH2-terminal sequence of CD59
may contribute to its activity.
The rationale in choosing the substituted residues in the
CD59 point mutants was as follows: (a) F23D. Aspartate is
smaller than phenylalanine, but has a consistent shape with
branching at Cg carbon; (b) Y36F. Phenylalanine is lacking
the hydroxyl group of tyrosine, and based on its conserva-
tion, this group may be important; (c) W40Y. Tyrosine is
smaller than tryptophane and the aromatic ring superim-
poses well onto the first ring of tryptophane; (d) L54N. As-
paragine is very close to leucine in shape and both side-
chains branch at Cg, although the arrangement at Cg is
tetrahedral for leucine and flat for asparagine. Of the four
point mutants prepared, one (Y36F) retained function, two
(F23D and L54N) disrupted function but preserved protein
topology, and one (W40Y) could not be stably expressed.
By building an explicit model of this mutant we found that
mutation of Trp40 to Tyr40 leads to a severe clash of the
hydroxyl group with the backbone H alpha atom of Val50.
This clash cannot easily be resolved and likely leads to the
loss of tertiary structure. The near full functional activity of
Y36F suggests either that this residue is not involved in
ligand binding, or that ligand interaction is primarily with
the phenol ring, rather than hydrogen bonding via the hy-
droxyl group. A further series of multiple residue mutations
within and around the hydrophobic groove will better de-
fine the active site.
It is not clear what function the N-linked carbohydrate of
CD59 may serve. It may be necessary for costimulation of
T cell activation (31, 32); it has been reported that the abil-
ity of CD59 to enhance CD58-dependent T cell responses
is dependent on the N-linked carbohydrate (33). Earlier re-
ports are in conflict over the requirement of N-linked gly-
cosylation for CD59 complement inhibitory function (28–
30). Here we confirm that glycosylation at Asn18 is not
required for the inhibition of C5b-9 assembly on the cell
surface. In fact, the absence of the carbohydrate enhances
slightly, but significantly, the complement inhibitory activ-
ity of the protein. The mechanism for this increase in in-
hibitory activity is not clear, but it is intriguing that mem-
brane sialic acid has recently been described as an acceptor
for C5b6, thus enhancing C5b-9–mediated lysis (34). The
absence of the sialylated carbohydrate of CD59 may there-
fore decrease, in a non-specific manner, C5b6 binding to
the cell surface. Whatever the mechanisms involved, our
data indicate that CD59 lacking N-linked carbohydrate yields
an improved inhibitor, an important consideration in de-
signing complement inhibitors for therapeutic applications
and in engineering animal organs for human transplantation.
CD59 interferes with the final stages of MAC assembly
either by binding to the a-chain of C8 in C5b-8 and
blocking the binding of C9, by binding to C9 in the na-
scent C5b-9 complex and preventing proper membrane in-
sertion and C9 polymerization, or by both mechanisms (3,
5, 6). If both mechanisms are operative, then the identifica-
tion of a single functionally important site in CD59 would
suggest that both C8a and C9 bind at this site. The puta-
tive CD59 binding site lies in the vicinity of a deep ex-
tended linear and hydrophobic groove. These characteristics
are consistent with the ligand being an unfolded polypep-
tide chain with exposed hydrophobic residues, as is postu-
lated to occur when C8 and C9 interact to form the MAC.
Of possible relevance, the molecular surface contains a long
tunnel under loop Asn8 to Cys13. There are two side
chains facing the inner surface of the tunnel, the conserved
Val35 as well as residues Asn, Ser, or Gln at position 72.
This channel may represent a secondary binding site, but
one that may not be required for its complement inhibitory
function.
The intense current interest in inhibitors of complement
is due to their potential use as anti-inflammatory agents and
for preventing unwanted complement-mediated cytolysis. In
addition to its role in hyperacute rejection of xenografts,
there is evidence indicating that complement-mediated cy-
tolysis is important in the pathogenesis of many autoimmune
and inflammatory diseases (35). Understanding precisely
how CD59 and other complement inhibitors function will
provide a foundation for designing functional inhibitors,
possibly multivalent and with enhanced inhibitory activity.
The identification of the active site for CD59 may also en-
Figure 8. Complement resis-
tance of CHO cells expressing
CD59 and site-specific CD59
mutants. Complement resistance
of CHO cell populations ex-
pressing similar levels of either
CD59 or CD59 containing the
indicated amino acid substitu-
tions was determined. Cells were
exposed to 10% NHS.752 Mapping the Active Site of DC59
able the design of CD59 inhibitors, quite possibly with af-
finities higher than those of its natural ligands (36); CD59
and other membrane-bound inhibitors of complement are
functionally expressed on tumor cells (37, 38), and inhibit-
ing CD59 on tumor cells may enhance their lysis when tar-
geted by complement activating tumor-specific antibodies.
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